EGFR and non-small cell lung carcinoma: Administering erlotinib provides better therapeutic benefits than standard chemotherapy for EGFR-mutated NSCLC.[6] It was approved by the Food and Drug Administration (FDA) as early as 2013, but only for EGFR-mutated NSCLC.